Latterell Venture Partners logo

Latterell Venture Partners

North America, California, United States, San Francisco

Description

Latterell Venture Partners (LVP) is a well-established venture capital firm based in San Francisco, California, with a singular focus on the healthcare sector. Founded in 1990, the firm has built a long track record of investing in and supporting innovative companies across various sub-sectors of healthcare, including biopharmaceuticals, medical devices, diagnostics, and healthcare services. LVP's investment strategy is primarily centered on seed and early-stage opportunities, aiming to identify and nurture promising ventures from their nascent phases.

The firm's deep specialization in healthcare allows its team to leverage extensive industry knowledge and networks to provide strategic guidance to its portfolio companies. LVP seeks out companies that are developing groundbreaking technologies or services with the potential to significantly impact patient care and the broader healthcare ecosystem. Their approach involves active engagement with founders, offering not just capital but also operational expertise and strategic insights to help navigate the complex landscape of healthcare innovation.

Over its three decades of operation, Latterell Venture Partners has successfully raised and managed multiple funds, accumulating over $1 billion in capital under management. This substantial capital base enables LVP to make meaningful investments in its portfolio companies. Typically, LVP's initial check sizes for new investments range from $1 million to $10 million, reflecting their commitment to providing significant early-stage funding to help companies achieve critical milestones. The firm's disciplined investment approach and long-term perspective have contributed to a strong reputation within the healthcare venture capital community.

Investor Profile

Latterell Venture Partners has backed more than 55 startups, with 0 new investments in the last 12 months alone. The firm has led 8 rounds, about 15% of its total and boasts 20 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Series A rounds (top funding stages).
  • Majority of deals are located in United States, South Korea.
  • Strong thematic focus on Health Care, Biotechnology, Medical Device.
  • Typical check size: $1M – $10M.

Stage Focus

  • Series B (35%)
  • Series C (24%)
  • Series A (22%)
  • Series Unknown (11%)
  • Series F (2%)
  • Series G (2%)
  • Series D (2%)
  • Private Equity (2%)
  • Series E (2%)

Country Focus

  • United States (98%)
  • South Korea (2%)

Industry Focus

  • Health Care
  • Biotechnology
  • Medical Device
  • Medical
  • Pharmaceutical
  • Therapeutics
  • Biopharma
  • Life Science
  • Manufacturing
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Latterell Venture Partners frequently co-invest with?

DeNovo Ventures
North America, California, United States, Saratoga
Co-Investments: 12
Domain Associates
North America, California, United States, San Diego
Co-Investments: 5
U.S. Venture Partners
North America, California, United States, Menlo Park
Co-Investments: 7
Adams Street Partners
North America, Illinois, United States, Chicago
Co-Investments: 10
Split Rock Partners
North America, Minnesota, United States, Minneapolis
Co-Investments: 5
Montreux Equity Partners
North America, California, United States, San Francisco
Co-Investments: 6
Morgenthaler Ventures
North America, California, United States, Menlo Park
Co-Investments: 14
P
North America, Illinois, United States, Northbrook
Co-Investments: 5
The Vertical Group
North America, New Jersey, United States, Basking Ridge
Co-Investments: 15
HLM Venture Partners
North America, Massachusetts, United States, Boston
Co-Investments: 6

Which angels does Latterell Venture Partners often collaborate with?

GM
North America, Texas, United States, Houston
Shared Deals: 1
AP
North America, New Jersey, United States, Hackensack
Shared Deals: 1

What are some of recent deals done by Latterell Venture Partners?

Viracta Therapeutics

Cardiff By The Sea, California, United States

Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.

BiopharmaBiotechnologyHealth CareMedicalOncologyPharmaceuticalTherapeutics
Series ENov 30, 2020
Amount Raised: $40,000,000
Pulmonx

Redwood City, California, United States

Pulmonx provides minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.

Health CareMedical Device
Series GMay 9, 2019
Amount Raised: $65,000,000
Aptinyx

Evanston, Illinois, United States

Aptinyx Inc. is a biopharmaceutical company.

BiopharmaBiotechnologyHealth CareMedical
Series BDec 18, 2017
Amount Raised: $70,000,000
Viracta Therapeutics

Cardiff By The Sea, California, United States

Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.

BiopharmaBiotechnologyHealth CareMedicalOncologyPharmaceuticalTherapeutics
Series BApr 4, 2017
Amount Raised: $18,400,000
Neuraltus Pharmaceuticals

Palo Alto, California, United States

Neuraltus Pharmaceuticals is focused on developing therapeutics that meet critical unmet needs in treating neurodegenerative diseases.

BiotechnologyHealth CarePharmaceutical
Series UnknownMay 24, 2016
Amount Raised: $14,938,357
Aptinyx

Evanston, Illinois, United States

Aptinyx Inc. is a biopharmaceutical company.

BiopharmaBiotechnologyHealth CareMedical
Series AMay 10, 2016
Amount Raised: $65,000,000
PerceptiMed

Mountain View, California, United States

PerceptiMed develops an advanced pill identification system designed to eliminate human errors in medication dispensing in pharmacies.

BiotechnologyHealth CareMedicalMedical Device
Series AMar 27, 2015
Amount Raised: $5,352,237
Naurex

Evanston, Illinois, United States

Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.

BiopharmaBiotechnologyTherapeutics
Series CDec 3, 2014
Amount Raised: $80,000,000
Transcend Medical

Menlo Park, California, United States

Transcend Medical focuses on the research and development of novel devices for the treatment of glaucoma.

Health CareMedicalMedical Device
Series CApr 2, 2014
Amount Raised: $29,000,000
Naurex

Evanston, Illinois, United States

Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.

BiopharmaBiotechnologyTherapeutics
Series BDec 17, 2012
Amount Raised: $38,000,000